Article
Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
The Cochrane database of systematic reviews - 7 Jul 2023
Gijtenbeek Rolof Gp, de Jong Kim, Venmans Ben Jw, van Vollenhoven Femke Hm, Ten Brinke Anneke, Van der Wekken Anthonie J, van Geffen Wouter H
Abstract excerpt
BACKGROUND: Most people who are newly diagnosed with non-small cell lung cancer (NSCLC) have advanced disease. For these people, survival is determined by various patient- and tumor-related factors, of which the performance status (PS) is the most important prognostic factor. People with PS 0 or 1 are usually treated with systemic therapies, whereas people with PS 3 or 4 most often receive supportive care....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.